| MBX |
MBX BIOSCIENCES, INC. |
Common Stock, $0.0001 par value per share |
12% |
$72,562,680 |
+$9,264,602 |
5,224,095 |
+15% |
Patrick J. Heron |
26 Sep 2025 |
| MAZE |
Maze Therapeutics, Inc. |
Common Stock - par value $0.001 per share |
9% |
$174,515,671 |
+$39,762,017 |
4,342,266 |
+30% |
Frazier Life Sciences Public Fund, L.P. |
31 Dec 2025 |
| IBIO |
iBio, Inc. |
Common Stock, $0.001 par value per share |
8.7% |
$2,344,160 |
|
1,953,467 |
|
Frazier Life Sciences Public Fund, L.P. |
09 Dec 2025 |
| PHAT |
PHATHOM PHARMACEUTICALS, INC. |
Common Stock, $0.0001 par value per share |
8.6% |
$70,447,299 |
|
5,985,327 |
0% |
James N. Topper |
01 Nov 2025 |
| NAMS |
NEWAMSTERDAM PHARMA COMPANY N.V. |
Ordinary Shares, nominal value EUR0.12 per share |
7.7% |
$245,264,825 |
+$36,858,297 |
8,623,939 |
+18% |
Frazier Life Sciences Public Fund, L.P. |
01 Nov 2025 |
| TRVI |
Trevi Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
7% |
$77,848,392 |
-$16,025,200 |
8,508,021 |
-17% |
Frazier Life Sciences Public Fund, L.P. |
30 Sep 2025 |
| KALV |
KALVISTA PHARMACEUTICALS, INC. |
Common Stock, $0.001 par value per share |
6.9% |
$42,222,226 |
+$12,986,864 |
3,466,521 |
+44% |
Frazier Life Sciences Public Fund, L.P. |
01 Nov 2025 |
| XLO |
Xilio Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
6.7% |
$3,086,472 |
-$2,286,600 |
4,676,472 |
-43% |
Frazier Life Sciences Public Fund, L.P. |
31 Dec 2025 |
| AURA |
Aura Biosciences, Inc. |
Common Stock, $0.00001 par value per share |
6.3% |
$20,523,185 |
+$4,675,216 |
4,032,060 |
+30% |
Frazier Life Sciences Public Fund, L.P. |
31 Dec 2025 |
| PVLA |
Palvella Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
6% |
$70,982,116 |
+$16,164,419 |
706,360 |
+29% |
Frazier Life Sciences Public Fund, L.P. |
31 Dec 2025 |
| VOR |
VOR BIOPHARMA INC. |
Common Stock, $0.0001 par value per share |
5.8% |
$17,973,688 |
|
2,258,001 |
|
Frazier Life Sciences Public Fund, L.P. |
18 Dec 2025 |
| ERAS |
Erasca, Inc. |
Common Stock, $0.0001 par value per share |
5.3% |
$21,355,029 |
-$10,702,679 |
15,038,753 |
-33% |
Frazier Life Sciences Public Fund, L.P. |
30 Jun 2025 |
| LXEO |
Lexeo Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
5.1% |
$27,478,154 |
+$4,642,294 |
3,698,271 |
+20% |
Frazier Life Sciences Public Fund, L.P. |
31 Dec 2025 |
| JBIO |
JADE BIOSCIENCES, INC. |
Common Stock, $0.0001 par value per share |
4.2% |
$11,949,495 |
+$379,228 |
1,384,646 |
+3.3% |
Frazier Life Sciences Public Fund, L.P. |
30 Sep 2025 |
| SVRA |
Savara Inc. |
Common Stock, par value $0.001 per share |
4.1% |
$49,390,844 |
+$9,458,692 |
8,343,048 |
+24% |
Frazier Life Sciences Public Fund, L.P. |
31 Dec 2025 |
| IRON |
DISC MEDICINE, INC. |
Common Stock, par value $0.0001 per share |
3% |
$57,339,676 |
|
1,026,489 |
|
Frazier Life Sciences Public Fund, L.P. |
30 Jun 2025 |
| ORIC |
ORIC Pharmaceuticals, Inc. |
Common Stock, $0.0001 par value per share |
2% |
$7,981,692 |
|
1,410,193 |
|
James N. Topper |
31 Mar 2025 |
| ELDN |
Eledon Pharmaceuticals, Inc. |
Common Stock |
2% |
$3,847,923 |
|
1,176,735 |
|
James N. Topper |
31 Dec 2024 |
| ANAB |
AnaptysBio, Inc. |
Common Stock |
0.5% |
|
|
|
|
Frazier Life Sciences Public Fund, L.P. |
31 Jan 2025 |
| MGNX |
MACROGENICS, INC. |
Common Stock, par value $0.01 per share |
0% |
$0 |
-$2,804,039 |
0 |
-100% |
Frazier Life Sciences Public Fund, L.P. |
31 Dec 2025 |
| MREO |
Mereo BioPharma Group plc |
Ordinary Shares, nominal value EURO0.003 per share, represented by American Depository Shares |
0% |
$0 |
-$21,404,255 |
0 |
-100% |
Frazier Life Sciences Public Fund, L.P. |
31 Dec 2025 |
| ADVM |
ADVERUM BIOTECHNOLOGIES, INC. |
Common Stock, $0.0001 par value per share |
0% |
$0 |
-$18,270,923 |
0 |
-100% |
Frazier Life Sciences Public Fund, L.P. |
09 Dec 2025 |
| ELEV |
Elevation Oncology, Inc. |
Common stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
Frazier Life Sciences Public Fund, L.P. |
23 Jul 2025 |
| ANTX |
AN2 THERAPEUTICS, INC. |
Common Stock |
0% |
$0 |
|
0 |
|
Frazier Life Sciences Public Fund, L.P. |
31 Dec 2024 |
| HLVX |
HILLEVAX, INC. |
Common Stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
Frazier Life Sciences Public Fund, L.P. |
17 Sep 2025 |
| PBYI |
Puma Biotechnology, Inc. |
Common Stock |
0% |
$0 |
|
0 |
|
Frazier Life Sciences Public Fund, L.P. |
31 Dec 2024 |